Program
pimurutamab
Also written as “HLX07”, “HLX43+HLX07” and “HLX43 DOSE 2 + HLX10 + HLX07”.
In Fosun Pharma’s pipeline, pimurutamab
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Nasopharyngeal Carcinoma · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Adenosquamous, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharmaits history only | 168 open or running | phase 3since Jan 4, 2026 | Jun 11, 2018 | Jul 28, 2027phase 2 · NCT07358585 |
| Henlix | 10 open or running | phase 1since Dec 27, 2015 | Dec 27, 2015 | none ahead |
- Named in Fosun Pharma’s own pipeline as
HLX07 (pimurutamab)
, phase 2, as of Sep 21, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Henlix only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 27, 2015First study: phase 1 study in Neoplasm MetastasisFirst studyNCT02648490 · 19 enrolled · United States, Taiwan
- Dec 9, 2019Named pimurutamabINNProposed as its International Nonproprietary Name in WHO's List 122
TargetBeta
“pimurutamab”the company's pipeline, read by Claude · source
“A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activa…”NCIt, read by Claude
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
The one study Henlix leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02648490Neoplasm Metastasis · United States, Taiwan | 1 | Completed | Jun 28, 2019 | 19 |
How it is read
Names in the registry
- “HLX07”, 12 entries
- “HLX43+HLX07”, 1 entry
- “HLX43 DOSE 2 + HLX10 + HLX07”, 1 entry
- “HLX43 DOSE 3 + HLX10 + HLX07”, 1 entry
- “HLX43 dose 1 + HLX07”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Colonic Neoplasms, 1 study
- Nasopharyngeal Carcinoma, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Carcinoma, Adenosquamous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.